Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 June 2015
Review of diabetes medicines called SGLT2 inhibitors
The Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of canagliflozin, dapagliflozin and empagliflozin, which are medicines known as SGLT2 inhibitors used to treat type 2 diabetes. The aim of the review is to evaluate the risk of diabetic ketoacidosis with these medicines. Diabetic ketoacidosis is a serious condition that usually develops in people with type 1 diabetes when insulin levels are too low.
More information is included in the table below.
|Agenda - PRAC draft agenda of meeting 8-11 June 2015|
Start of referral procedure
Article-20 procedure: SGLT2 inhibitors